{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:48046189-3962-412c-9aab-58df8ccaf532", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-10-15T04:55:00.612942Z", "firstcreated": "2026-10-15T04:50:08.564794Z", "pubstatus": "usable", "urgency": 5, "language": "en", "headline": "Personalized Neoantigen Vaccines Show Feasibility in Ovarian Cancer Trial", "byline": "Jenna Mercer", "located": "United States", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Science Official", "usageterms": "Monitoring item. Headline, short extract and the source link may be shown. Do not republish the full text.", "description_text": "A phase 1 trial found that personalized neoantigen vaccines combined with PD-1 blockade were feasible in high-grade serous ovarian cancer and produced tumor-specific immune responses in many patients, with resistance mechanisms linked to antigen presentation identified through cell-free DNA analysis.", "altids": {"mosaic": "48046189-3962-412c-9aab-58df8ccaf532", "story": "bb75d849-4143-440a-8c67-700be1dd207c", "slug": "personalized-neoantigen-vaccines-show-feasibility-in-ovarian-cancer-trial"}, "subject": [{"name": "Health", "rel": "direct", "literal": "health", "code": "medtop:07000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/07000000"}], "place": [{"name": "United States", "literal": "us", "code": "US", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "body_text": "A phase 1 trial found that personalized neoantigen vaccines combined with PD-1 blockade were feasible in high-grade serous ovarian cancer and produced tumor-specific immune responses in many patients, with resistance mechanisms linked to antigen presentation identified through ce", "extra_body_note": "Extract only — see rights.class = link_only.", "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:589d47ea-f62a-4fdf-aa70-bcf173d2c0ec", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "[Correspondence] Unmasking inequity: emergency presentations in ovarian cancer care – Authors’ reply", "description_text": "Ovarian Cancer Experts Flag Emergency Diagnoses as Barrier to Equitable Care", "copyrightholder": "en.wikipedia.org", "copyrightnotice": "Ovarian cancer", "usageterms": "File-level licence not yet resolved from Commons; fetch the original for exact terms.", "altids": {"wireva": "589d47ea-f62a-4fdf-aa70-bcf173d2c0ec"}, "extra": {"wireva:delivery_mode": "preview_and_link", "wireva:rights": {"licence": "Wikimedia — licence per file", "licence_url": "https://commons.wikimedia.org/wiki/Commons:Reusing_content_outside_Wikimedia", "licence_raw": "Wikipedia page image", "licence_verified_at": "2026-10-15T04:55:00.640199Z", "attribution_required": true, "attribution_text": "Ovarian cancer", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "en.wikipedia.org", "source_url": "https://en.wikipedia.org/wiki/Ovarian_cancer", "source_page_url": "https://en.wikipedia.org/wiki/Ovarian_cancer", "our_page_url": "https://scienceofficial.org/medicine/personalized-neoantigen-vaccines-show-feasibility-in-ovarian-cancer-trial/"}, "wireva:role": "lead"}, "renditions": {"preview": {"href": "https://nbg1.your-objectstorage.com/ckln/image-assets/1479f6e02a47e83f65a2418f624184c37083a97e4bf59e158c428bf07c0ae2e9.jpg", "mimetype": "image/jpeg", "width": 1280, "height": 853}, "source": {"href": "https://en.wikipedia.org/wiki/Ovarian_cancer", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:bb75d849-4143-440a-8c67-700be1dd207c", "slug": "personalized-neoantigen-vaccines-show-feasibility-in-ovarian-cancer-trial-20261015", "status": "developing", "languages": ["en"], "item_count": 1, "is_breaking": false}, "wireva:rights": {"class": "link_only", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Science Official", "canonical_required": true, "canonical_url": "https://scienceofficial.org/medicine/personalized-neoantigen-vaccines-show-feasibility-in-ovarian-cancer-trial/", "linkback_required": true, "licence": "", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 280, "decided_by_rule": "derivation_failed", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "single_source", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.", "independence_check": {"status": "failed", "score": 0.791, "checked_at": "2026-10-15T04:55:00.634109Z"}}, "wireva:publication": {"name": "Science Official", "domain": "scienceofficial.org", "country": "US", "url": "https://scienceofficial.org/medicine/personalized-neoantigen-vaccines-show-feasibility-in-ovarian-cancer-trial/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/48046189-3962-412c-9aab-58df8ccaf532", "html": "https://wireva.mib.news/item/48046189-3962-412c-9aab-58df8ccaf532/personalized-neoantigen-vaccines-show-feasibility-in-ovarian-cancer-trial/", "story": "https://wireva.mib.news/story/personalized-neoantigen-vaccines-show-feasibility-in-ovarian-cancer-trial-20261015/"}, "wireva:metrics": {"word_count": 571, "char_count": 3860, "reading_time_seconds": 276}}}